首站-论文投稿智能助手
典型文献
Verteporfin synergizes the efficacy of anti-PD-1 in cholangiocarcinoma
文献摘要:
Background:Cholangiocarcinoma(CCA)is one of the primary hepatobiliary malignant neoplasms with only 10%of 5-year survival rate.Promising immunotherapy with the blockade of immune checkpoints has no clear benefit in CCA.The inhibition of YAP1 signaling by verteporfin has shown encouraging results by inhibiting cell proliferation and inducing apoptosis.This study aimed to evaluate the potential benefit of the combination of verteporfin and anti-programmed cell death 1(PD-1)in CCA mouse model.Methods:We assessed the cytotoxicity of verteporfin in human CCA cell lines in vitro,including both intrahepatic CCA and extrahepatic CCA cells.We examined the in vitro effect of verteporfin on cell prolif-eration,apoptosis,and stemness.We evaluated the in vivo efficacy of verteporfin,anti-PD-1,and a com-bination of both in subcutaneous CCA mouse model.Results:Our study showed that verteporfin reduced tumor cell growth and enhanced apoptosis of hu-man CCA tumor cells in vitro in a dose-dependent fashion.Nevertheless,verteporfin impaired stemness evidenced by reduced spheroid formation and colony formation,decreased numbers of cells with alde-hyde dehydrogenase activity and positive cancer stem cell markers(all P<0.05).The combination of verteporfin and anti-PD-1 reduced tumor burden in CCA subcutaneous SB1 tumor model compared to either agent alone.Conclusions:Verteporfin exhibits antitumor effects in both intrahepatic and extrahepatic CCA cell lines and the combination with anti-PD-1 inhibited tumor growth.
文献关键词:
作者姓名:
Jianyang Fu;Nicole A McGrath;Jihye Lee;Xin Wang;Gagandeep Brar;Changqing Xie
作者机构:
Thoracic and Gastrointestinal Malignancies Branch,Center for Cancer Research,National Cancer Institute,National Institutes of Health,Bethesda,MD 20892,USA;Sandra and Edward Meyer Cancer Center,Weill Cornell Medicine,New York,NY 10065,USA
引用格式:
[1]Jianyang Fu;Nicole A McGrath;Jihye Lee;Xin Wang;Gagandeep Brar;Changqing Xie-.Verteporfin synergizes the efficacy of anti-PD-1 in cholangiocarcinoma)[J].国际肝胆胰疾病杂志(英文版),2022(05):485-492
A类:
alde,SB1
B类:
Verteporfin,synergizes,efficacy,cholangiocarcinoma,Background,Cholangiocarcinoma,CCA,primary,hepatobiliary,malignant,neoplasms,only,year,survival,rate,Promising,immunotherapy,blockade,immune,checkpoints,has,clear,benefit,inhibition,YAP1,signaling,by,verteporfin,shown,encouraging,results,inhibiting,proliferation,inducing,apoptosis,This,study,aimed,potential,combination,programmed,death,mouse,model,Methods,We,assessed,cytotoxicity,human,lines,vitro,including,both,intrahepatic,extrahepatic,cells,examined,stemness,evaluated,vivo,subcutaneous,Results,Our,showed,that,reduced,growth,enhanced,dose,dependent,fashion,Nevertheless,impaired,evidenced,spheroid,formation,colony,decreased,numbers,hyde,dehydrogenase,activity,positive,cancer,markers,all,burden,compared,either,agent,alone,Conclusions,exhibits,antitumor,effects,inhibited
AB值:
0.491172
相似文献
Overexpressed NEDD8 as a potential therapeutic target in esophageal squamous cell carcinoma
Jingrong Xian;Shiwen Wang;Yanyu Jiang;Lihui Li;Lili Cai;Ping Chen;Yue Liu;Xiaofei Zeng;Guoan Chen;Chen Ding;Robert M.Hoffman;Lijun Jia;Hu Zhao;Yanmei Zhang-Department of Laboratory Medicine,Huadong Hospital Affiliated to Fudan University,Shanghai 200040,China;Cancer Institute,Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China;Research Center on Aging and Medicine,Fudan University,Shanghai 200040,China;Shanghai Key Laboratory of Clinical Geriatric Medicine,Shanghai 200040,China;Department of Basic Science of Oncology,College of Basic Medical Sciences,Zhengzhou University,Collaborative Innovation Center of Henan Province for Cancer Chemoprevention,Zhengzhou 450001,China;School of Medicine,Southern University of Science and Technology,Shenzhen 518055,China;State Key Laboratory of Genetic Engineering,Human Phenome Institute,Institutes of Biomedical Sciences,School of Life Sciences,Zhongshan Hospital,Fudan University,Shanghai 200032,China;State Key Laboratory of Cell Differentiation and Regulation,Henan International Joint Laboratory of Pulmonary Fibrosis,Henan Center for Outstanding Overseas Scientists of Pulmonary Fibrosis,College of Life Science,Institute of Biomedical Science,Henan Normal University,Xinxiang 453007,China;Department of Surgery,University of California,San Diego 92101,USA;Anticancer Inc.,San Diego 92101,USA
JaponiconeA induces apoptosis of bortezomib-sensitive and -resistant myeloma cells in vitro and in vivo by targeting IKK β
Zilu Zhang;Chenjing Ye;Jia Liu;Wenbin Xu;Chao Wu;Qing Yu;Xiaoguang Xu;Xinyi Zeng;Huizi Jin;Yingli Wu;Hua Yan-Shanghai Institute of Hematology,Affiliated Ruijin Hospital of Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;VIP Health Center,Affiliated Ruijin Hospital of Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs,School of Pharmacy,Shanghai Jiao Tong University,Shanghai 200240,China;Hongqiao International Institute of Medicine,Shanghai Tongren Hospital/Faculty of Basic Medicine,Chemical Biology Division of Shanghai Universities E-Institutes,Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
Leyi Yao;Qian Zhao;Ding Yan;Ziying Lei;Yali Hao;Jinghong Chen;Qian Xue;Xiaofen Li;Qingtian Huang;Daolin Tang;Q.Ping Dou;Xin Chen;Jinbao Liu-Affiliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,State Key Laboratory of Respiratory Disease,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;Institute of Digestive Disease of Guangzhou Medical University,The Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan People's Hospital,Qingyuan 511518,China;School of Public Health,Guangzhou Medical University,Guangzhou,511436,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+T cell-mediated ferroptosis in castration-resistant prostate cancer
Xumin Zhou;Libin Zou;Hangyu Liao;Junqi Luo;Taowei Yang;Jun Wu;Wenbin Chen;Kaihui Wu;Shengren Cen;Daojun Lv;Fangpeng Shu;Yu Yang;Chun Li;Bingkun Li;Xiangming Mao-Department of Urology,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Second Department of Hepatobiliary Surgery,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Department of Urology,Minimally Invasive Surgery Center,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;Department of Urology,Guangzhou Women and Children's Medical Center,Guangzhou Medical University,Guangzhou 510623,China;Department of Urology,Peking University Shenzhen Hospital,Shenzhen 518036,China;Nursing Department,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China
Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo
Fanxiang Yin;Ran Zhao;Dhilli Rao Gorja;Xiaorong Fu;Ning Lu;Hai Huang;Beibei Xu;Hanyong Chen;Jung-Hyun Shim;Kangdong Liu;Zhi Li;Kyle Vaughn Laster;Zigang Dong;Mee-Hyun Lee-Department of Pathophysiology,School of Basic Medical Sciences,Zhengzhou University,Zhengzhou 450001,China;China-US(Henan)Hormel Cancer Institute,Zhengzhou 450008,China;Translational Medical Center,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;The Hormel Institute,University of Minnesota,Austin,MN 55912,USA;Department of Biomedicine,Health&Life Convergencen Science,BK21 Four,College of Pharmacy,Mokpo National University,Jeonnam 58554,Republic of Korea;The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention,Zhengzhou 450001,China;Department of General Surgery,the Affiliated Tumor Hospital of Zhengzhou University,Zhengzhou 450008,China;College of Korean Medicine,Dongshin University,Naju 58245,Republic of Korea
Pharmacodynamic,pharmacokinetic,and phase 1a study of bisthianostat,a novel histone deacetylase inhibitor,for the treatment of relapsed or refractory multiple myeloma
Yu-bo Zhou;Yang-ming Zhang;Hong-hui Huang;Li-jing Shen;Xiao-feng Han;Xiao-bei Hu;Song-da Yu;An-hui Gao;Li Sheng;Ming-bo Su;Xiao-li Wei;Yue Zhang;Yi-fan Zhang;Zhi-wei Gao;Xiao-yan Chen;Fa-jun Nan;Jia Li;Jian Hou-National Center for New Drug Screening,State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;Yantai Key Laboratory of Nanomedicine&Advanced Preparations,Yantai Institute of Materia Medica,Yantai 264000,China;Department of Hematology,Renji Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200127,China;Shanghai Center for Drug Metabolism and Pharmacokinetics Research,Shanghai 201203,China
Silibinin relieves UVB-induced apoptosis of human skin cells by inhibiting the YAP-p73 pathway
Wei-wei Liu;Fang Wang;Can Li;Xiao-yu Song;Wuxiyar Otkur;Yu-ying Zhu;Toshihiko Hayashi;Kazunori Mizuno;Shunji Hattori;Hitomi Fujisaki;Takashi Ikejima-Wuya College of Innovation,Shenyang Pharmaceutical University,Shenyang 110016,China;CAS Key Laboratory of Separation Science for Analytical Chemistry,Dalian Institute of Chemical Physics,Chinese Academy of Sciences,Dalian 116023,China;Department of Chemistry and Life science,School of Advanced Engineering,Kogakuin University,2665-1,Nakanomachi,Hachioji,Tokyo 192-0015,Japan;Nippi Research Institute of Biomatrix,Toride,Ibaraki 302-0017,Japan;Key Laboratory of Computational Chemistry-Based Natural Antitumor Drug Research&Development,Shenyang 110016,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。